Amneal Pharmaceuticals Inc logo

AMRX - Amneal Pharmaceuticals Inc Share Price

$4.83 -0.0  -0.4%

Last Trade - 15/01/21

Mid Cap
Market Cap £1.07bn
Enterprise Value £3.03bn
Revenue £1.38bn
Position in Universe 2325th / 6547
Unlock AMRX Revenue
Relative Strength (%)
1m +3.43%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -13.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
596 860.5 824.4 775.8 1,663 1,626 1,989 2,042 +22.2%
-50.2 -49.7 +12.9
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, AmnealPharmaceuticals Inc revenues increased 21% to $1.48B. Netloss before extraordinary items decreased 95% to $15.9M.Revenues reflect Speciality segment increase of 23% to$270.1M. Lower net loss reflects Generics segment incometotaling $134.8M vs. loss of $130.1M, Speciality segmentincome increase of 98% to $49.1M, Corporate and Othersegment loss decrease of 10% to $108.5M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


AMRX Revenue Unlock AMRX Revenue

Net Income

AMRX Net Income Unlock AMRX Revenue

Normalised EPS

AMRX Normalised EPS Unlock AMRX Revenue

PE Ratio Range

AMRX PE Ratio Range Unlock AMRX Revenue

Dividend Yield Range

AMRX Dividend Yield Range Unlock AMRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AMRX EPS Forecasts Unlock AMRX Revenue
Profile Summary

Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It operates in two segments, which include Generics and Specialty Pharma. The Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated October 4, 2017
Public Since March 16, 2009
No. of Shareholders: 205
No. of Employees: 5,500
Sector Healthcare
Industry Pharmaceuticals
Exchange New York Stock Exchange
Shares in Issue 299,745,330
Free Float (0.0%)
Eligible for
AMRX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AMRX
Upcoming Events for AMRX
Wednesday 5th May, 2021 Estimate
Amneal Pharmaceuticals Inc Annual Shareholders Meeting
Frequently Asked Questions for Amneal Pharmaceuticals Inc
What is the Amneal Pharmaceuticals Inc share price?

As of 15/01/21, shares in Amneal Pharmaceuticals Inc are trading at $4.83, giving the company a market capitalisation of £1.07bn. This share price information is delayed by 15 minutes.

How has the Amneal Pharmaceuticals Inc share price performed this year?

Shares in Amneal Pharmaceuticals Inc are currently trading at $4.83 and the price has moved by -9.72% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Amneal Pharmaceuticals Inc price has moved by -20.8% over the past year.

What are the analyst and broker recommendations for Amneal Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Amneal Pharmaceuticals Inc, there are there are currently 0 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Amneal Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Amneal Pharmaceuticals Inc next release its financial results?

Amneal Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Amneal Pharmaceuticals Inc dividend yield?

Amneal Pharmaceuticals Inc does not currently pay a dividend.

Does Amneal Pharmaceuticals Inc pay a dividend?

Amneal Pharmaceuticals Inc does not currently pay a dividend.

When does Amneal Pharmaceuticals Inc next pay dividends?

Amneal Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Amneal Pharmaceuticals Inc shares?

To buy shares in Amneal Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Amneal Pharmaceuticals Inc?

Shares in Amneal Pharmaceuticals Inc are currently trading at $4.83, giving the company a market capitalisation of £1.07bn.

Where are Amneal Pharmaceuticals Inc shares listed? Where are Amneal Pharmaceuticals Inc shares listed?

Here are the trading details for Amneal Pharmaceuticals Inc:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: AMRX
What kind of share is Amneal Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Amneal Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Amneal Pharmaceuticals Inc share price forecast 2021?

Shares in Amneal Pharmaceuticals Inc are currently priced at $4.83. At that level they are trading at 8.07% premium to the analyst consensus target price of 0.00.

Analysts covering Amneal Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.621 for the next financial year.

How can I tell whether the Amneal Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amneal Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -14.85%. At the current price of $4.83, shares in Amneal Pharmaceuticals Inc are trading at 12.05% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Amneal Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Amneal Pharmaceuticals Inc.

Who are the key directors of Amneal Pharmaceuticals Inc?

Amneal Pharmaceuticals Inc's management team is headed by:

J. Kevin Buchi - IND
Andrew Boyer - EVP
Joseph Greer - SVP
Sanjay Jain - CEX
Nikita Shah - CHO
Chirag Patel - PRE
Chintu Patel - CCE
Emily Alva - IND
Gautam Patel - DRC
Paul Meister - CHM
Jeffrey George - IND
John Kiely - IND
Anastasios Konidaris - CFO
Stephen Manzano - SVP
Apurva Saraf - SVP
Who are the major shareholders of Amneal Pharmaceuticals Inc?

Here are the top five shareholders of Amneal Pharmaceuticals Inc based on the size of their shareholding:

Fosun International Ltd Investment Advisor
Percentage owned: 14.58% (21.5m shares)
TPG Capital, L.P. Private Equity
Percentage owned: 10.98% (16.2m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 10.44% (15.4m shares)
Patel (Gautam) Individual Investor
Percentage owned: 8.84% (13.0m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.29% (10.8m shares)
Similar to AMRX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.